Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Ropivacaine Hydrochloride Liposome Suspension Injection

X
Trial Profile

A clinical trial of Ropivacaine Hydrochloride Liposome Suspension Injection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropivacaine (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Most Recent Events

    • 13 May 2021 According to a Luye Pharma Group media release, Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606), has been granted approval for clinical trials by the Centre for Drug Evaluation of China National Medical Products Administration.
    • 12 Mar 2021 New trial record
    • 08 Mar 2021 According to a Luye Pharma Group media release, clinical trial application for the company self-developed innovative formulation, Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606), has received formal acceptance from the Center for Drug Evaluation of the National Medical Products Administration in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top